CARDLYTICS, INC. CDLX Income Statement

Dec'19	Dec'18	Dec'17	Dec'16
Revenues
210,430	150,684	130,365	112,821
Costs and expenses:
FI Share and other third-party costs
118,080	85,371	73,247	66,285
Delivery costs
12,893	10,632	7,012	6,127
Sales and marketing expense
43,828	41,878	31,927	31,261
Research and development expense
11,699	16,210	12,150	13,902
General and administration expense
36,720	34,228	20,100	21,355
Depreciation and amortization expense
4,535	3,282	3,028	4,219
Exit Expense, Termination Of Agreement
-	-	-	25,904
Total costs and expenses
227,755	191,601	147,464	169,053
Operating loss
-17,325	-40,917	-17,099	-56,232
Other income (expense):
Interest (expense) income, net
-548	-3,264	-8,239	-6,170
Fair Value Adjustment of Warrants
0	6,760	581	32
Change in fair value of convertible promissory notes
0	0	-1,244	-786
Change in fair value of convertible promissory notes—related parties
0	0	6,213	-10,091
Foreign currency gain (loss)
729	-2,101	1,309	-2,385
Total other income (expense)
181	-12,125	-2,542	-19,464
Loss before income taxes
-17,144	-53,042	-19,641	-75,696
Income tax benefit
0	0	0	0
Net Income (Loss) Attributable to Parent
-17,144	-53,042	-19,641	-75,696
Adjustments to the carrying value of redeemable convertible preferred stock
0	157	5,743	982
Net loss attributable to common stockholders
-17,144	-53,199	-25,384	-76,678
Net loss per share attributable to common stockholders, basic and diluted (in USD per share)
-0.72	-2.79	-7.86	-32.48
Weighted-average common shares outstanding, basic and diluted (in shares)
23,746	19,060	3,230	2,361